Jay Lichter - Jun 14, 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director, 10%+ Owner
Signature
/s/ Maria Dobek, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
4
Date filed
6/16/2022, 04:31 PM
Previous filing
Jun 24, 2021
Next filing
Jun 23, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +12.5K $0.00 12.5K Jun 14, 2022 Common Stock 12.5K $10.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.